This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Arcus Biosciences (RCUS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (RCUS) Outperforming Other Medical Stocks This Year?
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Arcus Biosciences, Inc. (RCUS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Arcus Biosciences (RCUS) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RCUS) Outperforming Other Medical Stocks This Year?
Infinity's IPI-549 Gets Fast Track Tag for Urothelial Cancer
by Zacks Equity Research
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RCUS) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 13th
Infinity (INFI) Q4 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
by Zacks Equity Research
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
Infinity Initiates 2 Studies for Lead Candidate IPI-549
by Zacks Equity Research
Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -72.97% and -61.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).
Infinity Inks Deal With Roche for Phase II Study of IPI-549
by Zacks Equity Research
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of $35-$45 million.
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
Infinity and Arcus Ink Deal for Two Triple Combo Studies
by Zacks Equity Research
: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.